CTRL Therapeutics
Blood & Organ Banks · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
182 Howard St PMB 633, San Francisco, Ca...Website
www.ctrl-tx.comRevenue
<$5 MillionIndustry
About CTRL Therapeutics
cTRL Therapeutics is focused on developing innovative therapies for solid tumors by harnessing the power of cTRLs, a unique circulating T cell population capable of fighting cancer. Their proprietary platform, IsoQore, allows for the efficient isolation and extraction of polyclonal cTRLs from a single blood draw, eliminating the need for invasive surgical procedures. The company aims to simplify the complexities associated with solid tumor cell therapy development, manufacturing, and administration. With a team of experts in cell therapy discovery and development, cTRL Therapeutics is committed to redefining treatment options for the 90% of cancers represented by solid tumors.Explore more
CTRL Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to CTRL Therapeutics
Compare insights from companies similar to CTRL Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CTRL Therapeutics Tech Stack
A closer look at the technologies used by CTRL Therapeutics
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CTRL Therapeutics
Sign Up For FreeTo access detailed company insights
cTRL Therapeutics is focused on developing innovative therapies for solid tumors by harnessing the power of cTRLs, a unique circulating T cell population capable of fighting cancer. Their proprietary platform, IsoQore, allows for the efficient isolation and extraction of polyclonal cTRLs from a single blood draw, eliminating the need for invasive s... Read More
